AstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal Post author:Sam Post published:December 28, 2017 Post category:BioPharma ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace You Might Also Like 4C Medical Tech Exceeds $8 Million Convertible Note Financing Round Led By July 18, 2017 Gilead HCV Woes Continue and Investors are Spooked October 26, 2017 Real Estate Developers Eye Boston’s South End for Life Science Campus November 13, 2017
